SCHEMBL14728152

SCHEMBL14728152

Cc1ccc2c(c1)c(CC(=O)NCCCNS(=O)(=O)c1ccc(/N=N/c3ccc(N(C)C)cc3)cc1)c(C)n2C(=O)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 13/20 0.53
PTGS1 P23219 5/20 0.53
PTGES O14684 1/20 0.53
ALOX5 P09917 1/20 0.53
CA12 O43570 4/20 0.52
CA1 P00915 4/20 0.52
CA2 P00918 4/20 0.52
CA4 P22748 4/20 0.52
CA9 Q16790 4/20 0.52
HRH4 Q9H3N8 1/20 0.51
APP P05067 1/20 0.49
BCHE P06276 1/20 0.49
ACHE P22303 1/20 0.49
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL861693 0.92 CA12 (0.64) PTGS2PTGS1PTGESALOX5CA12
SCHEMBL839246 0.87 PTGES (0.63) PTGS2PTGS1PTGESALOX5CA12
SCHEMBL861692 0.87 PTGES (0.63) PTGS2PTGS1PTGESALOX5CA12
SCHEMBL14351094 0.84 CA12 (0.54) PTGS2PTGS1PTGESALOX5CA12
SCHEMBL14728035 0.81 PTGS2 (0.55) PTGS2PTGS1PTGESALOX5CA12
SCHEMBL14351089 0.79 CA12 (0.56) PTGS2PTGS1PTGESALOX5CA12
SCHEMBL10147685 0.79 CA12 (0.52) PTGS2PTGS1PTGESALOX5CA12
SCHEMBL17369568 0.78 PTGS2 (0.74) PTGS2PTGS1HRH4APPBCHE
SCHEMBL17369551 0.76 PTGS2 (0.69) PTGS2PTGS1CA12CA1CA2
SCHEMBL17369567 0.76 PTGS2 (0.69) PTGS2PTGS1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865130-B2 Methods and compositions for diagnostic and therapeutic targeting of COX-2 VANDERBILT UNIVERSITY (US) 2014-10-21 US disclosed
US-20130052138-A1 METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 VANDERBILT UNIVERSITY (US) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052138-A1 METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 PTGS2, PTGES2, PTGER2 PTGS2 1/4885PTGS1 5/4885PTGES 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.